gvs 111 has been researched along with alpha-synuclein in 1 studies
| Studies (gvs 111) | Trials (gvs 111) | Recent Studies (post-2010) (gvs 111) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 91 | 2 | 31 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gharibyan, AL; Jia, X; Liu, Y; Morozova-Roche, LA; Öhman, A; Olofsson, A | 1 |
1 other study(ies) available for gvs 111 and alpha-synuclein
| Article | Year |
|---|---|
Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity.
Topics: alpha-Synuclein; Amyloid; Cell Line, Tumor; Cell Survival; Dipeptides; Humans; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Polymerization | 2011 |